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Background: Huntington’s disease (HD) is an inherited neurodegenerative condition which 
affects movement, coordination and cognitive functioning. Psychological difficulties are 
commonly experienced, however psychological interventions have been little researched with 
this population. We investigated the feasibility of conducting a randomised controlled trial 
(RCT) of mindfulness-based cognitive therapy (MBCT) with people with the HD genetic 
mutation, either pre-manifest (before onset of movement symptoms) or at an early disease 
stage. Specifically we evaluated the willingness of participants to be recruited into and 
complete the intervention; the acceptability of the study measures in relation to completion; 
the feasibility of offering the standard MBCT course to people with HD; the acceptability of 
the intervention; and estimated effect sizes. 
Methods:   Participants were recruited from two UK HD centres and took part in an 8-week 
course of MBCT, with three reunions throughout the following year. Stress, depression, 
anxiety and mindfulness were measured pre-, mid-, and post-course, at 3 months and 1 year. 
Sleep quality of life, positive affect and coping were measured pre- and post-course, at 3 
months and 1 year. Descriptive data and approximate effect sizes were calculated. Interviews 
were conducted post-course and at one year and data pertaining to the acceptability of the 
course were extracted.  
Results: Twelve participants took part in two groups; all were pre-manifest. Levels of 
depression and anxiety were low pre-course leaving little room for improvement. Changes in 
stress and in some aspects of mindfulness were medium to large. The qualitative data 
suggested participants rated the course highly and found it helpful and no changes to the 
standard course were needed. Recruitment levels were below those anticipated. Most 
measures were found to be acceptable. 
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Conclusions: Although the course was acceptable to those who took part, given the 
difficulties in recruiting and the rarity of HD, conducting an RCT of MBCT teaching groups 
in person does not seem feasible. However, alternative modes of course delivery (e.g. online) 
would allow the recruitment of people from a greater geographical area and may make an 
RCT feasible; this revised focus would be suitable for future feasibility studies. 
Trial registration: ClinicalTrials.gov identifier NCT02464293, registered 8 June 2015, 
https://clinicaltrials.gov/ct2/show/NCT02464293 
 





Huntington’s disease (HD) is an inherited neurodegenerative condition which affects 
movement, coordination and cognitive functioning, with emotional difficulties also 
commonly experienced. It is believed to affect as many as 12.3 per 100,000 people of 
European descent (1). Each child of an affected person has a 50% chance of inheriting the 
condition; diagnosis, however, is not confirmed by a positive genetic test but on the onset of 
motor problems, which can be decades later. Age of diagnosis is typically around 35-55, with 
time from diagnosis to death around 20 years (2). Many people at various stages of HD 
(including those who carry the gene mutation but are pre-manifest) experience low mood, 
anxiety and other psychological difficulties (e.g., 3, 4-6). Indeed, alongside functional 
capacity, depression and anxiety may be the main factors which contribute to reduced health 
related quality of life, more so than discrete motor problems, or cognitive impairment (7). In 
addition, reports from patients suggest emotional and social concerns are important for 
individuals with the condition at the pre-manifest stage (e.g. anxiety about symptoms and 
impact of the condition on self and family, difficulties with acceptance of the condition and 
self-confidence, lack of support, perceived negative attitudes of others and limited public 
awareness) and similar concerns remain throughout the disease course (8). Medication may 
be effective to alleviate psychological difficulties for some people (9), but its efficacy has not 
been conclusively proven (10) and it is not suitable for all. Furthermore, at least some would 
prefer not to take it, or to prolong the period without it (11). 
Although it is commonly presumed that biological factors are the main determinants of 
psychological distress in people with HD, several studies have indicated that, while these 
may indeed be important, psychological factors are also significant. For example both beliefs 
about the illness and coping mechanisms have been shown to be significant predictors of 
individuals’ mental health (12-14). Such psychological beliefs and coping patterns can be 
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adaptively changed using psychological interventions. For example cognitive-based 
psychological therapies such as cognitive behavioural therapy (CBT) presume cognitions and 
appraisals are key in experiences of physical illness and associated distress and that these, 
along with associated coping patterns, can be modified (15). Such propositions are supported 
to some extent by empirical studies which have documented changes in beliefs, appraisals 
and coping strategies some of which mediate outcomes in a variety of health conditions 
following CBT e.g. (16-24). 
However, little progress has been reported on the development of psychological interventions 
in HD despite the fact that people with HD have expressed an interest in psychological 
approaches (25) and these are currently being successfully developed for people with other 
neurological conditions with low mood, e.g., Parkinson's disease (PD) and multiple sclerosis 
(MS) (26). Indeed, currently no feasibility study or pilot has been published in HD using any 
specific psychological therapy for psychological outcomes. Despite this, a recent qualitative 
study indicated that individuals with the HD gene who were receptive to the idea of 
psychological therapy did feel that non-pharmacological options should be open to them (11).  
While a number of psychological approaches might be useful for individuals affected by HD, 
this study reports a feasibility assessment of mindfulness-based cognitive therapy (MBCT) 
for depression, with anxiety and stress also considered as outcome measures. This particular 
therapy combines mindfulness practices with elements of cognitive therapy. During the 
course individuals are taught to focus their attention in a particular way and to be present in 
the moment, bringing a non-judgemental stance to thoughts, feelings and experiences (27). 
MBCT is most usually offered in a group format, with eight sessions of two hours, with 
reunion meetings also available after the end of the course. The group format is commonly 
reported as providing useful support (e.g., 28) and it is not unusual for groups to maintain 
contact after the formal course has ended.  
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Through engaging in MBCT it is hypothesised that individuals become aware of unhelpful 
thought processes and beliefs, learn to decentre and disengage from them by focusing on 
present moment experiences, become aware that thoughts and feelings are temporary mental 
events rather than facts, and relate to their self and experiences more compassionately (29). 
By standing back and bringing awareness and acceptance to experiences including distress,  
greater emotional regulation as well as emotional, behavioural and cognitive flexibility can 
be achieved and as a result a greater (and more adaptive) range of coping strategies can be 
employed (30).  
Although originally developed to help reduce relapse rates among people with prior recurrent 
depression (31, 32), MBCT has been increasingly used to help people with current difficulties 
(33-35). Some, albeit limited, empirical evidence exists for the proposed mechanisms (29) 
including increased cognitive reappraisal ability (i.e. ability to change how one thinks about 
an emotional stimulus) (36), reduced reactivity to social stress (37) and a reduction in 
disengagement coping styles (38). Qualitative findings suggest MBCT can lead to changed 
patterns of coping (39), with an increased sense of personal agency and control (28). MBCT 
and a similar programme, mindfulness-based stress reduction (MBSR)(40), have been 
investigated in other neurological conditions where low mood and anxiety, for example, may 
also be the result of neurological changes as well as psychological and social factors, where 
individuals are adjusting to a physical health problem, and where difficulties with movement 
and cognition may also be present. For example, in a pilot RCT with people with PD, a 
programme based on MBCT reduced depression (41) and participants with PD have also 
reported improvements in self-management and psychological wellbeing following MBCT 
(39). Programmes based on MBSR or MBCT for people with MS have shown improvements 
in a variety of outcomes including depression, anxiety and stress (42). One study on MBSR 
for people with motor neurone disease/amyotrophic lateral sclerosis found improvements in a 
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number of measures of distress (43). Modifications have sometimes been necessary, for 
example to reduce the physical component of the course (mindful movement) or reduce 
cognitive burden e.g. (41, 44). 
Feasibility studies are an increasingly useful way of indicating whether an intervention is 
acceptable and whether study parameters are practical. Given the lack of psychological 
interventions for individuals with HD, it was considered that a feasibility study was needed 
first to ascertain whether a future randomised controlled trial (RCT) of MBCT could be 
undertaken. The aim of this study was therefore to test the feasibility of conducting a future 
RCT on MBCT for people with the HD gene expansion who were pre-manifest or at an early 
disease stage.     
Methods 
Design 
This study was designed to test the feasibility of a future RCT. Recent guidance (45) suggests 
that feasibility studies (as opposed to pilot studies) do not have to be randomised and should 
not just be a version of the intended randomised controlled trial with a smaller N, i.e. the 
study ‘in miniature’. In particular this study set out to assess: the willingness of participants 
to be recruited into and complete the intervention; the acceptability of the study measures in 
relation to completion; the feasibility of offering a group intervention to people with HD 
following the standard MBCT format; the acceptability of the intervention; and estimated 
effect sizes. 
The study adopted a pre-post single group design with an embedded qualitative component, 
with follow-up up to a year. The main quantitative outcomes of interest were depression, 
anxiety and stress, along with mindfulness. Additional outcomes assessed were positive 
affect, sleep, coping and quality of life. However, as is typical for feasibility studies (46), the 
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study was not powered to detect significant changes, rather the data were used descriptively 
and to provide an estimate of effect sizes.  
The qualitative data collected provided information on acceptability. An in-depth analysis of 
the participants' experience will be reported in a separate publication.  
Participants 
Participants had to be aged 18 or over and had to have been tested and found to have the 
relevant mutation on the huntingtin gene, meaning they would go on to develop symptoms of 
the disease in the future (if they had not already). Participants could be pre-manifest or 
symptomatic at stage 1 (i.e. score 11 or 12 or 13 on the Total Functional Capacity Scale (47) 
which is part of the Unified Huntington’s Disease Rating Scale (48). Being at stage 1 means 
individuals are still able to function at home and at work and handle their financial affairs and 
domestic responsibilities. Participants had to have clinical signs of depression or low mood, 
identified in their medical notes or other information recorded at their last clinic visit (i.e. the 
clinician’s impression was that low mood or depression was present). Participants were 
excluded if they had active suicidal intent. There had to be no significant changes in 
medication in the 6 weeks prior to starting the MBCT intervention.  
Sample size 
We aimed to recruit 15 participants for an MBCT course for pre-manifest individuals and 15 
participants for an MBCT course for those at an early disease stage, from two HD centres in 
the North of England. MBCT classes for research often have approximately 12 participants 
per class (49) and therefore we were aiming for similar numbers, allowing for some attrition. 
It is advisable that mindfulness groups are not too small - both to ensure they remain classes 




Potential participants were invited to participate by a member of their clinical team when 
attending routine clinic appointments. In addition, where patients had already consented to be 
contacted about research, they were contacted by telephone, email or letter to be told about 
the research. Potential participants could then contact the research team themselves to hear 
more about the research or give their consent for the clinical team to pass their details on to  
the research team who then contacted the potential participant. The mindfulness teacher 
described the nature of the course and what it entailed, and if they still wished to participate, 
a member of the research team met with them at home or another convenient location to take 
consent and complete the baseline measures.  
Intervention 
The MBCT course was taught according to guidance in the manualised version of MBCT 
(49) by a registered mindfulness teacher. The course involves eight classes of two hours each, 
at weekly intervals as well as about an hour a day of home practice. As is common in trials 
(49), the recommended day of silent practice between classes 6 and 7 was omitted due to 
limited funding. MBCT involves learning how to be mindful via formal meditations 
including sitting meditations (becoming aware of the breath), the body scan and mindful 
movement, as well as more informal practices which help participants become mindful in 
everyday activities. In the year following the course, three reunion meetings at 3-monthly 
intervals were offered where participants revisited the principles and practice of mindfulness, 
discussed any difficulties and recommitted to their practice (49).  
Feasibility objectives 
The objectives of the study were as follows: 
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1. To ascertain the willingness of participants to be recruited into and complete the 
intervention, thus to examine issues of recruitment, retention of participants and 
attendance at the mindfulness courses 
2.  To ascertain acceptability of the study measures by examining any difficulties with 
completion  
3. To ascertain whether it was feasible to offer the standard MBCT course to individuals 
with HD  
4. To ascertain the acceptability of the intervention 
5. To estimate effect sizes. 
 
Outcome measures 
Depression and anxiety were measured using the 14 item Hospital Anxiety and Depression 
Scale (HADS; 50) and stress with the 7-item stress subscale of the short form of the 
Depression, Anxiety and Stress Scales (DASS; 51). Mindfulness was measured by the 39 
item Five Facets of Mindfulness Questionnaire  (FFMQ; 52). This scale has five subscales – 
observing, describing, acting with awareness, non-judging and non-reacting - which measure 
the different aspects of mindfulness and is one of the most widely used measure of 
mindfulness which captures these different dimensions (53). Coping was measured by the 
brief (28-item) COPE (54); sleep quality assessed using the 19-item Pittsburgh Sleep Quality 
Index (PSQI; 55); positive affect from the 10-item positive affect subscale from the Positive 
and Negative Affect Schedules, asking about the previous week (PANAS; 56); and quality of 
life measured using the 26-item abbreviated scale of the World Health Organization Quality 
of Life Instrument (WHOQOL-BREF; 57, 58).  
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All items were based on self-report and were collected using the above well-validated 
measures. All measures were administered pre-, post-, 3 months post- and one-year post-
course. Depression, anxiety, stress and mindfulness were also administered mid-course.  
Quantitative analysis 
Quantitative data were tabulated for descriptive purposes. Given the small sample size, a non-
parametric approach was used to calculate effect size data (r = Z/√ (N )) , where Z is the 
standardised test-statistic from a Wilcoxon signed rank test and N is the sample size (59), 
along with the associated 95% confidence interval. The r values are calculated for the 
timepoint as compared to baseline. 
Qualitative data  
Qualitative interviews were completed with participants immediately post-course and one-
year post-course to explore acceptability. An approach guided by framework analysis (60) 
was used to extract themes relevant to the issue of acceptability. This approach is useful for 
answering pragmatic evaluative questions (60). 
Results 
Recruitment Rate 
As pharmaceutical trials which particularly targeted those with early stage HD were ongoing 
at the same time as this study, the number of potential participants identified by referring 
clinicians was not as high as originally anticipated. By October 2015 we had recruited 
sufficient individuals to go ahead with one course – these were all pre-manifest individuals 
(cohort 1). Acceptance was approximately 1 in 3 of those approached. Three people who 
initially expressed interest could not attend (one not contactable, one could not do the day we 
had considered most accessible for most people - a Saturday - and one lived too far away). 
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Eleven people started the course and one left after 1 session (due to a non-related health 
issue), the other 10 completed.  
As only 10 participants had completed the first course and they were all pre-manifest, we 
decided to recruit for a second course starting October 2016, allowing the entry of both 
manifest and pre-manifest individuals. However, recruiting for a second group proved much 
more challenging. Most eligible pre-manifest patients who were interested had already taken 
part in the first cohort. We decided to involve a second smaller centre (the one geographically 
closest to the larger centre) to try to increase the potential pool. Unfortunately, this had fewer 
eligible potential participants than had been anticipated (eight in total). 
Thus for cohort 2, two centres were involved. From the first centre, from the participants 
identified as eligible, five individuals expressed an interest and of these two were then not 
contactable. Two withdrew before the first day (one actively withdrew and one did not 
attend), one took part and completed. From the second centre, of the eight eligible individuals 
four were interested. One person was symptomatic and felt the MBCT course location was 
too far to travel to and one person withdrew before the course started. One individual 
attended one session then withdrew (feeling it was not for them) and one person continued 
and completed. 
As we were finding it hard to recruit sufficient numbers for cohort 2, participants from cohort 
1 were also invited to return for a second course and three people accepted this invitation. It 
is not unusual for people to repeat mindfulness training (40) and this is often of further 
benefit to the person themselves as well as to others new to the approach. As one of the new 
participants from the second cohort commented: “it was quite good having some people 
doing it for the second time ‘cos you could tell they’d picked up a lot from the first time and 
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they had like useful tips and things and that was good”. Three repeaters started the course and 
two completed (one withdrew due to a non-related health issue).  
Thus in summary, cohort 2 had six participants who started the course; three new participants 
and three participants from cohort 1 who opted to repeat the course and four participants 
completed (two new participants and two repeaters). The flow of participants can be seen in 
Figure 1. 
Figure 1 about here please 
Generally reasons given for non-participation included scheduling (the course was run on a 
weekend, to allow more people with work commitments to participate, however, this meant 
that some parents of young children could not participate due to childcare difficulties and 
others were working) and travel distance. Other patients suggested it was too difficult to 
attend 8 weeks of 2 hour sessions because of other commitments. Some people were not 
interested, some could not conceive that the course would be of benefit and some did not 
wish to take part in a group intervention.   
Participants 
The data presented are based on 12 participants who completed the course (10 from cohort 1 
and the two new completers from cohort 2). Demographics of those who completed the 
course are given in Table 1.  
Table 1 around here please 
Eight females and 4 males completed the MBCT course; all identified as White British or 
White Irish. They were aged 24-64 years (M = 47 years; SD = 12 years), with 6 in full time 
employment, 2 in part time employment and 4 not currently employed or retired. Regarding 
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highest education, three had degree level qualifications or similar, 2 A levels, 1 a school 
leavers certificate, 4 O’ levels/GCSE or similar and 2 no formal qualifications.  
All participants were pre-manifest, in the sense that none had manifest motor signs of HD. 
According to their self-report, at the start of the course, the time since their genetic testing 
ranged from 1-21 years (M = 9 years) and seven participants were taking antidepressant 
medication. 
As can be seen from Table 2, despite an inclusion criterion which stipulated that potential 
candidates should have expressed some difficulties with mood, most participants scored 
relatively low on the mood outcomes pre-intervention.  
Intervention and attendance 
No adaptations to the standard course were made. When doing mindful movement 
participants were advised not to undertake anything that could cause physical harm (e.g., not 
to walk too slowly if they were concerned about their balance). 
Attending a minimum of five classes was considered evidence of course completion. Of the 
14 participants who started classes, 12 met this criterion for completion (the other two left 
after one class). 
Measures completion  
No difficulties were reported by the 12 participants with the measures of depression, anxiety, 
stress, mindfulness, coping, sleep and positive affect. For the HADS and FFMQ completion 
numbers were as follows: pre n=12; mid n=12; post n=11; 3-months n=11; 1-year n=11. 
For the DASS stress subscale completion numbers were pre n=12; mid n=10; post n=11; 3-
months n=11; 1-year n=10. For the brief COPE completion numbers were pre n=12; post 
n=11; 3-months n=11; 1-year n=11, for the PSQI pre n=12; post n=11; 3-months n=11; 1-
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year n=10 and for the PANAS positive subscale pre n=12; post n=10; 3-months n=11; 1-
year n=11. 
However, only nine participants completed the quality of life measure at baseline. The use of 
this measure requires that data are shared with the measure’s authors and includes the 
participant’s date of birth and this was made clear in the consent process. As a result, three 
participants opted not to complete it. Completion numbers were pre n=9; post n=8; 3-months 
n=8; 1-year n=8. 
Effect sizes  
A descriptive summary of the outcomes can be seen in Table 2 and Table 3 along with effect 
sizes. 
Tables 2 & 3 around here please  
Inspection of the effect sizes (.1= small; .3 = medium; .5 = large) indicates that of the 
psychological distress outcomes (depression, anxiety and stress), the consistently larger 
effects were for stress. In relation to mindfulness, all effect sizes were in the predicted 
direction and for several of the subscales – e.g., non-judging and non-reacting – these were 
consistently large across time.  
Changes were generally minimal for coping, sleep and positive affect. The main effect sizes 
of note are mainly in the COPE at one year, where they are large for decreases in behavioural 
disengagement and denial and increases in positive reframing and religious coping. However, 
the confidence intervals for all outcomes are wide so there is considerable uncertainty in 
these findings. 
Acceptability of the intervention 
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Eleven people took part in the immediate follow-up interviews and ten in those at one-year. 
The following themes related to acceptability were extracted. 
Overall appraisal of the classes 
Everyone gave a positive appraisal of their experience of learning mindfulness and most 
enjoyed the classes. 
“The classes […] they were really good. They were helpful” (P9, Immediate Follow Up, 
(FU)) 
“I was quite surprised actually how enjoyable it was really and how helpful it was” (P5, 
Immediate FU) 
“Each lesson I was learning something new about yourself a bit and about how your mind 
works” (P4, Immediate FU) 
Meeting others with HD 
At recruitment several people had expressed anxiety about meeting other participants who 
were symptomatic and thus seeing how the disease might develop. However, in the event 
everyone who took part was pre-manifest (i.e. not yet showing motor symptoms), which was 
described as a relief. As HD is rare, most people appreciated the chance to meet with others 
who had the genetic mutation. 
“[The course] seemed really useful and it was good to meet other people in a similar 
situation” (P22, immediate FU) 
“I mean, even just sitting in a group working together with people that have got HD as well 




The three reunions that were offered in the year following the course were also described by 
participants as beneficial, both for the group support and for providing an opportunity for 
people to renew their commitment to practising mindfulness, particularly if practice had 
fallen away over the preceding three months. 
“I felt the support from the group, and the empathy from the group was very, very powerful.” 
(P1, one year FU) 
“I think they [the reunions] really did help to, yeah, get back on track and reconnect.” (P22, 
one year FU) 
Continuing practice 
Following the end of the 8 weeks of classes, most people intended to continue to practise 
mindfulness, to some extent, whether that was informally in their everyday lives or more 
formally doing the specific mindfulness practices. 
“I’m feeling really strongly about mindfulness and I’m practising it mostly daily because I 
really feel it’s helped me” (P10, Immediate FU) 
“I will definitely keep on with it. Whether or not I do it as frequently. I don’t know” (P8, 
Immediate FU) 
At one year, people were still using the skills, although some to a greater extent than others: 
“I’ve never gone more than a few days without doing it [formal mindfulness practice]” (P1, 
One year FU) 
“It’s not like a daily thing. Just whenever I get stressed it just feels like it’s a quick way to get 




There was general consensus that it was beneficial to meet off the hospital site. However, due 
to financial constraints, the venue was quite basic, with some issues with the heating (needed 
in the UK winter when participants are stationary) and some participants commented that an 
alternative, more pleasant venue would have been preferable. 
Participants who took the course twice 
Two participants who took and completed the course twice reported particular benefit from 
the intervention. Not only did they attend the course twice, they also continued to attend both 
sets of reunion classes and both started attending mindfulness events outside of the research 
study. Both described learning mindfulness through the course as “life-changing”, with one 
person additionally describing it “one of the most profound experiences” (P3, one year FU). 
Discussion 
This study set out to investigate the feasibility of performing an RCT on MBCT with 
individuals with the HD gene who were pre-manifest or at an early disease stage. In particular 
the aims were: to assess the willingness of participants to be recruited into and complete the 
intervention; to assess the acceptability of the study measures; to assess the feasibility of 
offering a group eight week intervention to people with HD; to assess the acceptability of the 
intervention; and to estimate effect sizes. The findings will be discussed in relation to these 
specific aims as well as the broader issues which arose relating to a possible future RCT or 
future feasibility and pilot work. 
Challenges in Recruitment 
We were able to run two courses of MBCT. Cohort 1 consisted of 11 participants (10 
completers) who were recruited from one large UK centre. Recruiting for this course was 
relatively successful, with uptake approximately 1 in 3 (i.e. approximately a third of eligible 
pre-manifest patients from the centre who were approached opted to take part). However 
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recruiting for the second course was much more difficult. Despite also involving a second 
smaller centre only three new participants started the second course (along with three 
repeating participants). 
As is often the case, relationships were key, and recruitment was most successful when done 
in person via staff who knew the patients (or at least the patients and lead consultant had a 
good relationship and therefore patients were interested in research). Furthermore, in the 
large centre, the main recruiting staff had knowledge of mindfulness and were keen to 
promote it.  Finally, perhaps recruitment was more straightforward in the larger centre where 
research participation was routine and embedded into clinic visits.     
Recruiting a group of people with a relatively rare condition is challenging from a geographic 
perspective. Patients can travel over two hours to get to appointments at a main centre and to 
travel this distance on a weekly basis is a considerable burden. This is perhaps even more so 
when the early symptoms could include problems with fatigue or motivation and some mild 
cognitive problems. Finally it can be hard for some people with a genetic medical condition 
to conceive that a psychological intervention could help their mood difficulties, particularly if 
they view them as an inevitable part of their condition (11), and thus considerable work is 
needed promoting the research and potential for psychological intervention. 
The inclusion of individuals in cohort 2 who had completed cohort 1 was a pragmatic 
decision to ensure the class could run and to allow us to collect further information on 
feasibility. As noted above, repeating MBCT classes is not unusual and often happens in 
clinical practice. However, to our knowledge the effect of repeaters on class outcomes has not 
been studied and therefore it is not possible to ascertain for sure if it affects outcomes. If 
conducting a full-sized RCT inclusion of repeaters would need to be considered and it may be 
prudent to include solely new participants.  
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This study recruited mainly from one of the largest HD centres in the UK. Considering future 
studies, a recruitment rate of 1 in 3 at a large HD centre would probably be sufficient to 
permit one course of MBCT to take place (with approximately 10-12 participants) with pre-
manifest individuals. However, given the low rate of distress reported, at least on the 
measures adopted here (discussed further below), recruiting sufficient pre-manifest 
individuals reporting high levels of distress would not be feasible from one centre. 
Furthermore, if twice this number were required to permit a control group for an RCT, then 
recruiting sufficient numbers of pre-manifest individuals, regardless of distress, would not be 
possible from one centre. Recruiting individuals at an early disease stage was completely 
unsuccessful so currently it appears unfeasible to do an RCT on MBCT recruiting this way 
for them.  
Acceptability of measures  
Participants were able to complete most of the measures and no participants reported them as 
particularly burdensome. However, it would have been beneficial to capture other aspects of 
wellbeing, for example apathy and irritability which have been discussed in relation to HD (3, 
5). Furthermore, the qualitative findings, along with discussions in the classes, suggested the 
benefits participants experienced were not captured well in the quantitative measures. Future 
studies may benefit from considering outcomes other than anxiety and depression, and also 
considering capturing a broader understanding of wellbeing. Indeed focusing on positive 
outcomes, such as improving wellbeing or resilience, may be a more useful outcome for this 
group for future studies. Furthermore, instead of the COPE, which looks at a broad range of 
specific coping strategies, it may be preferable to target the coping strategies theorised as 
directly influenced by mindfulness. Some of these are captured in the FFMQ but other 
concepts that could be examined include problem-focused and approach-avoidance coping 
and experiential avoidance (38, 61) or coping flexibility (62).   
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A further issue relates to the use of the HADS. At the time of conception of the project the 
HADS was recommended for identifying depression in people with HD (63) and was in use 
for other international large scale studies in HD, e.g. REGISTRY (http://www.euro‐
hd.net/html/registry) and ENROLL‐HD (https://www.enroll‐hd.org/). However, more 
recently the factor structure has been questioned (64), including in HD (65), with suggestions 
that the total score may be more appropriate as a measure of distress (64) and that in HD only 
certain items should be included (65). Thus use of these other scoring approaches should be 
considered for general distress and other measures of anxiety and depression may be better 
for measuring these outcomes specifically.  
The one measure that caused some difficulty was the WHOQOL-BREF (57, 58). Some 
participants opted not to complete it as they were uncomfortable with their data being shared 
with the measure’s authors and thus with individuals outside of the immediate research team. 
Furthermore, on reflection, the broad nature of this measure (including, for example, 
measuring environmental quality of life) could reduce the sensitivity to change from this 
particular intervention. For future trials of this nature an HD specific health-related quality of 
life measure, such as the HD Health-Related Quality of Life Questionnaire (66) may be more 
appropriate.  
Feasibility of a group eight-week MBCT intervention  
The standard MBCT programme (without the all-day class) was able to be implemented 
without any changes. All participants who completed the course were able to attend the 
minimum of five sessions required for course completion. This would suggest that for pre-
manifest individuals, the standard MBCT course could be appropriate for future work. 
However, given the low levels of distress (at least reported on the measures), it may be that a 
mindfulness-based intervention with a greater focus on increasing flourishing, rather than 
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reducing depression, may warrant further exploration. Two such interventions also delivered 
as eight-week courses are MBSR and Mindfulness for Life: the former has been extensively 
researched, while the latter, developed by prominent MBCT researchers and others, though 
promising is rather new, therefore less well established. 
The exclusion of the all-day class was partly a pragmatic decision but is also common in 
research studies (49) although future pilot studies may wish to consider including this if the 
design permits (e.g. the contact time does not need to be controlled compared to another trial 
arm which can be problematic with this element). As the time commitment was already an 
issue for some participants here, the views of participants regarding this element may need to 
be sought in feasibility work. 
Regarding the eight-week commitment, this was not problematic for those who attended; 
indeed several commented that they would have preferred a longer timeframe. However, 
during recruitment, some potential participants declined due to difficulties relating to access 
and the time commitment required. Alternative ways of accessing the course which do not 
require attendance in person may need to be considered to make MBCT more accessible, 
such as a delivery via group online video call (67, 68) or a hybrid model with part delivered 
online and part in person. Such a delivery mode would also remove the need for all 
participants to live in the same geographical area and online recruitment methods could also 
be considered. Both of these would need exploring first in further feasibility work, 
particularly given the apparent importance of relationships and connection to the clinic 
mentioned during recruitment.  
For those who took part in the intervention, the group format was a facilitator of completion 
and engagement. However, feedback from the study recruiters indicated that the group aspect 
did not appeal to some individuals and this was one of several factors which reduced 
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enrolment. Group interventions are widely acknowledged to have the potential for 
dichotomising potential clients (69) with many participants gaining substantially from the 
group element and others finding the group setting overwhelming or uncomfortable, and this 
study provides further evidence of this. MBCT was originally designed as a group 
intervention and groups can also be cost-effective but individual mindfulness interventions 
are being explored in other health conditions (e.g., 70), so this could be considered for future 
work. Generally, this highlights the need for a variety of therapies to be available for people 
with HD. 
Acceptability of the intervention  
The participants who participated in the intervention were clearly willing to try a 
psychological intervention, despite the dominant narrative that psychological difficulties in 
HD are largely neurologically mediated. The effect sizes and qualitative data indicated that 
participants were able to learn mindfulness skills and the good attendance at classes and 
reunions and continued practice of mindfulness by participants suggest the intervention was 
acceptable to most of them. This suggests that pursuing mindfulness-based approaches for 
future work is worthwhile. 
Effect sizes  
The calculation of effect sizes was complicated by a number of factors relating to 
recruitment. The levels of depression at the start of the course were actually relatively low as 
a group and thus there was little room for improvement (and therefore for effect sizes to be 
high). All participants had expressed some level of psychological distress in their last visit to 
the clinic, however for some people their mood had improved since that visit (perhaps due to 
medication or a change in life situation) and for others, the measures did not appear 
consistently to reflect the participant’s state of mind. Indeed for one or two participants, their 
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scores worsened over time as they became more aware of their mood (and verbally reported 
being more “in touch” with how they were feeling). The difficulty of capturing increased 
insight in therapy (and thus sometimes worsening mood scores) is a common problem in 
therapeutic outcome (e.g., 71). Finally, it is acknowledged that caution is needed when 
drawing any conclusions on effect sizes from feasibility studies (72). Given these difficulties, 
alongside the other issues in this feasibility study, the current effect size calculations are 
probably not useful for powering future studies.  
Conclusions 
In summary, it would not be feasible to perform an RCT following the precise method of the 
current study. However, a number of recommendations can be made, some of which could be 
further tested in future feasibility or pilot work. 
• No symptomatic individuals were recruited and thus it may be that recruiting them for 
this type of intervention is not feasible. However, alternative avenues of recruitment 
for symptomatic individuals may be useful to investigate before this can be 
concluded.  
• Group setting can be positive for many participants, but will not appeal to all and 
therefore individual psychological therapy might need to be available. 
• Given the very positive experiences for those who were willing and able to attend, we 
think mindfulness-based therapy as an approach is an area of research that should be 
pursued further for individuals with the HD gene. We are particularly interested in 
trying to develop an approach that allows greater flexibility in terms of access but also 
retains some of the benefits of participants meeting face-to-face. It may be that a 
hybrid model with some face-to-face meetings but also taking elements of the current 
online courses available and/or apps may be a useful avenue to pursue.  
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• Alternatively, a supported online version of the MBCT course would allow a greater 
number of people access and so could cover a much wider geographical area and 
allow people to “attend” in a more flexible way, and may be useful given the rarity of 
the condition. As part of this approach, it may be possible to recruit through online 
channels (e.g. via HD charities) which could broaden the potential participant pool. 
Such an approach would need feasibility work to explore the willingness of 
participants to be recruited outside of HD clinics and to explore whether participants 
found this mode of accessing therapy acceptable.  
• While eight weeks represents a considerable commitment, and was not possible for 
some potential participants, we would be hesitant to suggest a shorter course as there 
is a risk that individuals might not be able to engage fully with the concepts in a 
shorter time. Indeed, many of the current participants reported that they thought the 
course could be longer.  
• Individuals with the HD gene might also be able to access generic MBCT courses 
(and other similar mindfulness-based interventions) if available in their local area, 
whether through the NHS (in the UK) or registered private providers. However, given 
the very specific psychological challenges faced by this group – and also supported by 
the qualitative feedback we received from participants – much value resides in 
offering evidence-based interventions tailored to this group. As a compromise, it may 
be possible to run groups with individuals with conditions that are similar in terms of 
difficulties in movement, cognition, behaviour and psychological distress (e.g., 
Parkinson’s disease or Parkinson’s plus disorders), although this would need further 
research to investigate acceptability to participants and effectiveness. 
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Table 1: Demographics and clinical information 
Age Mean (SD), range 47 (11.7), 24-64 
Gender (n)    
Male 4 
Female  8 
Ethnicity (n)  
White British 11 
White Irish 1 
Employment (n)  
Full time 6 
Part time 2 
Not employed or retired 4 
Education (n)  
Degree or similar 3 
A levels 2 
School leavers’ cert. 1 
O’ levels/GCSEs 4 
No formal qualifications 2 
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Time since genetic test in years  Mean (SD), range 9 (7.4), 1-21 






Table 2: Anxiety, depression, stress and mindfulness 
 Pre Mid Post 3 months post 1 year post 
 M SD M SD r r( CI) M SD r r( CI) M SD r r( CI) M SD r r( CI) 
















HADS-D 5.42 5.28 5.83 3.90 0.21 -0.42, 
0.70 
5.45 5.75 0.17 -0.48, 
0.70 
5.73 4.71 0.12 -0.51, 
0.67 
5.00 3.79 0.08 -0.55, 
0.65 
















FFMQ                   
Observing 25.67 5.69 26.67 4.48 0.24 -0.39, 
0.71 
29.00 5.31 0.38 -0.28, 
0.80 
30.27 3.88 0.55 -0.07, 
0.86 
30.8 3.97 0.66 0.10, 
0.90 
Describing 23.92 6.43 26.83 6.29 0.43 -0.19, 
0.80 
27.73 6.74 0.80 0.39, 
0.95 
26.73 8.33 0.45 -0.21, 
0.83 







22.08 9.10 24.08 5.96 0.35 -0.28, 
0.77 
25.55 7.54 0.29 -0.37, 
0.76 
26.18 7.55 0.62 0.03, 
0.89 




20.75 6.21 24.25 6.03 0.58 0.00, 
0.86 
25.64 6.27 0.60 0.01, 
0.88 
27.64 7.43 0.75 0.28, 
0.93 




16.58 5.33 21.33 3.60 0.69 0.20, 
0.91 
22.91 4.57 0.82 0.42, 
0.95 
22.64 3.70 0.77 0.31, 
0.94 
24.1 3.14 0.85 0.50, 
0.96 
Pre n=12; mid n=12 (except DASS-S, n=10); post n=11; 3-months n=11; 1-year n=11 (except DASS-S n=10). 
HADS-A Hospital Anxiety and Depression Scale - Anxiety Score; HADS-D Hospital Anxiety and Depression Scale- Depression Score; DASS-
S Depression Anxiety and Stress Scale – Stress Score; FFMQ Five Factor Mindfulness Questionnaire. r is effect size (r = Z/√ (N ), where Z is 
the standardised test-statistic from a Wilcoxon signed rank test and N is the sample size. r(CI) is 95% confidence interval for r. A negative r 
indicates improvement in depression, anxiety and stress and a positive r indicates improvement in mindfulness. DASS-21 stress scores are 





Table 3: Positive affect, coping, sleep and quality of life 
 Pre Post 3 months post 1 year post 
 M SD M SD r r(CI) M SD r r 
(CI) 
M SD r r(CI) 














COPE               










4.64 2.16 -0.38 -
0.80, 
0.28 
Active coping 5.25 1.66 5.73 2.00 0.42 -
0.24, 
0.81 
5.64 1.86 0.13 -
0.51, 
0.68 
6.00 1.90 0.30 -
0.37, 
0.76 










2.45 0.94 -0.60 -
0.88, 
0.00 
Substance use 3.17 2.12 3.27 2.05 0.00 -
0.60, 
0.60 
3.64 1.91 0.39 -
0.27, 
0.80 







4.67 2.39 5.27 1.85 0.39 -
0.28, 
0.80 
5.00 2.28 0.11 -
0.53, 
0.66 





























2.82 1.17 -0.60 -
0.88, 
0.00 















4.83 1.53 5.55 1.92 0.44 -
0.21, 
0.82 
5.36 1.69 0.28 -
0.39, 
0.75 
6.27* 1.62 0.61 0.01, 
0.89 








4.91 2.02 0.00 -
0.60, 
0.60 








4.73 2.24 -0.20 -
0.71, 
0.46 















Religion 3.67 2.42 4.91 2.26 0.74 0.26, 
0.93 
4.36 2.11 0.46 -
0.19, 
0.83 
4.73 2.69 0.67 0.12, 
0.91 










3.18 1.32 -0.47 -
0.83, 
0.18 
               
PSQI Total 
score 
















WHOQOL               





65.6 22.5 0.00 -
0.70, 
0.70 
64.3 28.3 -0.18 -
0.79, 
0.60 








56.5 17.6 0.00 -
0.70, 
0.70 








62.5 31.2 0.00 -
0.70, 
0.70 










66.0 19.8 -0.48 -
0.89, 
0.34 
Pre n=12 (except WHOQOL n=9); post n=11 (except PANAS-P n=10; WHOQOL n=8); 3-months n=11 (except WHOQOL n =8); 1-year 




PANAS-P positive subscale of the Positive and Negative Affect Scale. PSQI Pittsburgh Sleep Quality Index WHOQOL Brief version of the 
World Health Organization Quality of Life Instrument.  r is effect size (r = Z/√ (N ), where Z is the standardised test-statistic from a Wilcoxon 
signed rank test and N is the sample size. r(CI) is 95% confidence interval for r. A positive r indicates an increase in positive affect on the 
PANAS-P, an increase in quality of life on the WHOQOL and an increase in use of each coping strategy on the COPE. A negative r indicates 














Centre 1 only 
 
Cohort 2 
Centre 1 and 2 
 
14 interested Centre 1: 5 new interested 
Centre 2: 4 new interested 
3 from cohort 1 interested in 
repeating course 
3 declined to participate 
• 2 practical reasons 
• 1 not contactable 
Centre 1: 4 declined  
• 2 not contactable 
• 1 did not attend first 
session 
• 1 changed mind 
Centre 2: 2 declined 
• 1 practical reasons 
• 1 changed mind 
11 completed baseline 
measures and started course 
1 withdrew after 1 session 
due to unrelated health 
issues 
10 completed course 
3 new completed baseline 
measures and started course.  
3 repeaters also started course 
9 completed follow up 
measures 
• 1 not contactable 
2 new completed course 
2 repeaters completed course 
9 completed 3 month 
measures 
 
9 completed 1 year 
measures 
 
1 withdrew after 1 session 
as disliked intervention 
1 repeater withdrew due to 
non-related health issue 
 
2 new completed follow up 
measures 
2 new completed 3 month 
measures 
 





Repeaters in cohort 2 had completed the intervention in cohort 1 and took part in the intervention a 
second time. Only data for the new completers in cohort 2 (not the repeaters) are included in the 
results section.  
 
 
